PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS

Benzer Materyaller

• PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS
  Yazar:: M. Breccia, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
  Yazar:: Thomas Ernst, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-08-01)
• Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients
  Yazar:: Gaëlle Fossard, ve diğerleri
  Baskı/Yayın Bilgisi: (2016-03-01)
• Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
  Yazar:: Harnicar S, ve diğerleri
  Baskı/Yayın Bilgisi: (2014-08-01)
• Nilotinib cause moyamoya disease in the treatment of chronic myelogenous leukemia during chronic phase: A case report
  Yazar:: Jin-ping Liang, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-09-01)